Verve Therapeutics

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan and Burt A. Adelman in 2018 and is headquartered in Boston, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

A trial for the company's lead therapy was put on hold.

Why Verve Therapeutics' Stock Dropped 26.33% on Monday

Verve Therapeutics (NASDAQ: VERV ) stock is taking a beating on Monday following bad news from the FDA. The unfortunate news for VERV shareholders is the FDA putting the company's VERVE-101 Investigational New Drug Application (IND) on hold.

Why Is Verve Therapeutics (VERV) Stock Down 28% Today?

U.S. officials halted Verve's plan to begin testing in people a gene-editing approach to high cholesterol, leading VERV stock to crash. The post Verve Crashes After FDA Halts Plan To Test Gene Editor In People appeared first on Investor's Business Daily.

Verve Crashes After FDA Halts Plan To Test Gene Editor In People

Verve Therapeutics (VERV) delivered earnings and revenue surprises of -5.33% and 81.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Verve Therapeutics (VERV) Reports Q3 Loss, Lags Revenue Estimates

VERVE-101 Investigational New Drug Application Placed on Hold by U.S. Food and Drug Administration

Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results

Verve Therapeutics announced disappointing lab results for its CRISPR gene-editing approach to high cholesterol, and VERV stock skidded. The post Why Shares Of CRISPR-Focused Verve Therapeutics Just Took A Grim Turn appeared first on Investor's Business Daily.

Why Shares Of CRISPR-Focused Verve Therapeutics Just Took A Grim Turn

AppLovin Corp

Enovix Corporation

NeoGenomics

1Life Healthcare

Prometheus Biosciences

Signify Health

Sotera Health

Scotts Miracle-Gro

WeWork

Mid-cap companies are those that fall between small and large cap companies. Thus, they are more stable than small-cap companies and, at the same time, offer higher growth opportunities than large-cap companies.

These Were The Five Best And Worst Performing Mid-Cap Stocks In Q3 2022

Alnylam Pharmaceuticals

Amgen

BioCryst Pharmaceuticals

Beam Therapeutics

CRISPR Therapeutics

Graphite Bio

Ionis Pharma

Intellia Therapeutics

Pfizer

Regeneron Pharmaceuticals

Takeda Pharmaceutical

Vertex Pharmaceuticals

Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

Cathie Wood-led Ark Investment Management on Friday raised its stake in clinical stage genetics medicine company Verve Therapeutics Inc (NASDAQ: VERV) via two of its exchange-traded funds.

Cathie Wood's Ark Invest Adds $23M Of Verve Therapeutics Shares As Stock Drops 10% In A Month - Verve Therapeutics (NASDAQ:VERV)

Adobe

TuSimple Holdings

Velo3D

Exchange-traded fund (ETF) manager Cathie Wood made headlines this week after she announced that she would cede control of her role as portfolio manager for the 3D Printing ETF (BATS: PRNT ) and the ARK Israel Innovative Technology ETF (BATS: IZRL ). Both ETFs carry over $100 million in assets under management.

The Top 5 Stocks Cathie Wood Is Buying This Week

Ginkgo Bioworks Holdings

The founder and CEO of ARK Investment Management is buying up drugmaker stocks like they're going out of style.

Cathie Wood Goes Shopping for Biotech: 3 Stocks She Just Bought

CAMBRIDGE, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the clearance of its Clinical Trial Authorisation (CTA) application by the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for VERVE-101 as a potential treatment for patients with heterozygous familial hypercholesterolemia (HeFH). HeFH is a prevalent and potentially life-threatening genetic subtype of atherosclerotic cardiovascular disease (ASCVD) characterized by extremely high blood levels of disease-driving low-density lipoprotein cholesterol (LDL-C).

Verve Therapeutics Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia

ARKG component added to flagship fund. Meaningful position would top 7% of outstanding shares.

Verve Therapeutics: Cathie Wood Adds To ARKK

DraftKings

Roblox

Teladoc

It's been a difficult year for Cathie Wood stocks and exchange-traded funds, as the ARK Innovation ETF (NYSEARCA: ARKK ) has lost over 50% of its market capitalization. The losses have been driven by supply chain inefficiencies, inflation, and subsequent interest hikes to combat inflation.

5 Top Stocks Cathie Wood Is Buying Right Now

The biotech's long-winded rally continued this week.

Why Verve Therapeutics Stock Crushed It This Week

CAMBRIDGE, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced new preclinical data supporting the nomination of the company's second product candidate, VERVE-201. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver, a key regulator of cholesterol and triglyceride metabolism, with a precise A-to-G base pair DNA change. Verve is initially developing VERVE-201 for the treatment of homozygous familial hypercholesterolemia (HoFH), a rare genetic subtype of atherosclerotic cardiovascular disease (ASCVD) characterized by extremely high blood low-density lipoprotein cholesterol (LDL-C), as well as for patients with ASCVD who have not achieved goal LDL-C with oral therapy and a PCSK9 inhibitor. The preclinical data will be highlighted on August 29, 2022 in a poster session during the European Society of Cardiology 2022 Congress in Barcelona.

Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress

Over $300 Million in Capital Added to Balance Sheet, Supporting an Operating Runway into Second Half of 2025

Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results

CAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the closing of its previously announced upsized underwritten public offering of 9,583,334 shares of its common stock at a public offering price of $27.00 per share, which includes 1,250,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. The total gross proceeds of the offering were $258.8 million, before deducting underwriting discounts and commissions and offering expenses payable by Verve. All of the shares in the offering were sold by Verve.

Verve Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

The gene-editing company is getting an infusion of cash.

Why Shares of Verve Therapeutics Shot Up 44.9% This Week

Verve Therapeutics (VERV) enters into a four-year collaboration with Vertex Therapeutics to develop a gene-editing program targeted at liver disease for an upfront payment of $60 million.

Verve (VERV) Up on Gene Editing Collaboration With Vertex

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Verve Therapeutics Inc (NASDAQ: VERV) announced an exclusive, four-year global research collaboration to discover and develop an in vivo gene editing program for undisclosed liver disease. Under the terms of.

Verve Therapeutics, Vertex Join Forces For Liver Disease-Focused Gene Program

CAMBRIDGE, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of its upsized underwritten public offering of 8,333,334 shares of its common stock at a public offering price of $27.00 per share, for total gross proceeds of approximately $225.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Verve. All of the shares in the offering are being sold by Verve. In addition, Verve has granted the underwriters a 30-day option to purchase up to 1,250,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on July 25, 2022, subject to the satisfaction of customary closing conditions.

Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock. All of the shares are being offered by Verve. In addition, Verve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Verve Therapeutics Announces Proposed Public Offering of Common Stock

Verve to Receive $25 Million Upfront Payment and $35 Million Equity Investment, as Well as Potential Milestones and Royalties Verve to Receive $25 Million Upfront Payment and $35 Million Equity Investment, as Well as Potential Milestones and Royalties

Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease

Phase 1b Clinical Trial, heart-1, Now Underway and Enrolling Patients with Heterozygous Familial Hypercholesterolemia in New Zealand

Verve Therapeutics Doses First Human with an Investigational In Vivo Base Editing Medicine, VERVE-101, as a Potential Treatment for Heterozygous Familial Hypercholesterolemia

News for Verve Therapeutics Stock (VERV)